Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
China Pharma Holdings, Inc. (CPHI)
Price—Loading quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M | $10.9M | $10.9M | $12.3M | $13.2M | $15.6M | $20.4M | $22.1M | $32.8M | $54.5M | $81.2M | $74.4M |
| Gross profit | −$131,950 | −$2.0M | −$281,085 | −$493,916 | $349,270 | $2.0M | $1.5M | $2.0M | $2.5M | $3.2M | $1.5M | $2.7M | −$480,919 | $14.1M | $29.0M | $30.3M |
| Gross margin | −3.18% | −43.84% | −4.01% | −6.09% | 3.62% | 17.97% | 13.57% | 16.02% | 18.68% | 20.67% | 7.20% | 12.05% | −1.47% | 25.82% | 35.71% | 40.71% |
| Research & development | $280,901 | $283,942 | $240,080 | $185,858 | $318,964 | $377,964 | $229,637 | $172,384 | $90,474 | $365,969 | $961,897 | $2.8M | $1.7M | $438,662 | — | — |
| Operating expenses | $3.1M | $2.6M | $2.5M | $3.1M | $3.2M | $4.5M | $21.9M | $12.4M | $21.1M | $11.7M | $17.4M | $41.5M | $18.1M | $8.3M | $7.3M | $6.1M |
| Operating income | −$3.2M | −$4.6M | −$2.8M | −$3.5M | −$2.9M | −$2.6M | −$20.4M | −$10.4M | −$18.7M | −$8.2M | −$14.3M | −$38.8M | −$18.6M | $5.9M | $22.0M | $24.7M |
| Operating margin | −78.16% | −101.32% | −39.25% | −43.79% | −29.67% | −23.73% | −186.82% | −84.73% | −141.38% | −52.38% | −70.26% | −175.11% | −56.72% | 10.83% | 27.14% | 33.16% |
| EBITDA | −$1.7M | −$2.0M | $1,833 | −$848,444 | $227,310 | $101,177 | −$17.5M | −$7.2M | −$15.4M | −$5.1M | −$10.7M | −$37.0M | −$17.0M | $7.4M | $23.2M | $26.2M |
| EBITDA margin | −41.88% | −43.52% | 0.03% | −10.47% | 2.36% | 0.93% | −160.01% | −58.30% | −116.47% | −32.61% | −52.58% | −167.04% | −51.80% | 13.52% | 28.58% | 35.18% |
| Net income | −$3.2M | −$4.7M | −$3.1M | −$4.0M | −$3.4M | −$2.9M | −$20.7M | −$10.8M | −$19.3M | −$9.2M | −$15.4M | −$39.6M | −$20.0M | $4.6M | $19.3M | $23.4M |
| Net profit margin | −76.91% | −104.58% | −43.91% | −49.02% | −35.26% | −26.38% | −189.51% | −87.18% | −145.91% | −58.97% | −75.70% | −178.69% | −60.99% | 8.47% | 23.74% | 31.48% |
| Basic EPSper basic share | -$0.74 | -$2.71 | -$9.10 | -$37.80 | -$37.00 | -$35.00 | -$240.00 | -$125.00 | -$220.00 | -$105.00 | -$175.00 | -$455.00 | -$230.00 | $55.00 | $220.00 | $270.00 |
| Diluted EPSper diluted share | -$0.74 | -$2.71 | -$9.10 | -$37.80 | -$37.00 | -$35.00 | -$240.00 | -$125.00 | -$220.00 | -$105.00 | -$175.00 | -$455.00 | -$230.00 | $55.00 | $220.00 | $270.00 |
Owners
Reported shareholders
0.31%of listed shares
CITADEL ADVISORS LLC125.45K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
CITADEL ADVISORS LLC | 0.31%125.45K shares |
TWO SIGMA SECURITIES, LLC | 0.09%35.67K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.04%15.05K shares |
JANE STREET GROUP, LLC | 0.03%13.89K shares |
Ground Swell Capital, LLC | 0.03%10.61K shares |
UBS Group AG | <0.01%3.11K shares |
EFG International AG | <0.01%40 shares |
DANSKE BANK A/S | <0.01%1 shares |
Percentages use 40.52M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data